Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

NCT02027337 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Polycystic Ovarian Syndrome
Hyperandrogenism
Menstrual Irregularities

Interventions

DRUG: 20 mcg ethinylestradiol /3 mg drospirenone
DRUG: 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit
DRUG: 30 mcg ethinylestradiol/3 mg drospirenone
DRUG: 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit
DRUG: 35 mcg ethinylestradiol/2 mg cyproterone
DRUG: 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit

Sponsor

Tyumen State Medical Academy